✓ Plata cu cardul restabilită — finalizare securizată prin Privacy Shield

Oxyspas

✅ Reduces bladder spasms
✅ Relieves urinary urgency
✅ Decreases urinary frequency
✅ Improves bladder control
✅ Treats overactive bladder

Oxyspas contains Oxybutynin Chloride.

Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență  · Ultima recenzie: mai 2026

Cumpără mai mult, economisește mai mult Preț pe tabletă
Selectați o doză mai sus pentru a vedea prețurile pachetelor.
Plată criptată
Plățile în crypto reduc prețul cu 10%
Livrare discretă în întreaga lume
1.400+ clienți · 50+ țări

Quick Answer — What is Oxyspas?

Oxyspas conține oxybutynin chloride — a tertiary amine anticholinergic / antimuscarinic drug used to treat overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence. Available in 2.5 mg and 5 mg tablets. Oxybutynin is the oldest and most-prescribed OAB drug worldwide. It blocks M3 muscarinic acetylcholine receptors on the bladder detrusor, reducing involuntary contractions during filling. Standard adult dose: 5 mg two-to-three times daily (10-15 mg total/day); start at 2.5 mg twice daily in the elderly or anyone susceptible to anticholinergic side effects. Efecte secundare cele mai frecvente: dry mouth (50%+), constipation, blurred vision, drowsiness, dizziness, urinary retention. Use with caution in adults aged 65+ — the 2023 American Geriatrics Society Beers Criteria classifies oxybutynin as “potentially inappropriate” in older adults due to anticholinergic-related fall, cognitive, and delirium risk. Mirabegron is the preferred first-line OAB drug in older patients.

Ce beneficii oferă MedsBase: Producător certificat WHO-GMP · Ambalaj discret · Livrare la nivel mondial · Peste 1.400 de recenzii verificate ale clienților

📦 Fiecare comandă este acoperită de politica noastră de Politica noastră de Reexpediere Garantată — dacă coletul dumneavoastră nu sosește în 20 de zile lucrătoare, îl relivrăm.

🔒 Checkout criptat · 💳 Procesor verificat · 🚚 Livrare worldwide · ⭐ 4,9/5 de la peste 1.400 de clienți

De ce să comanzi de la MedsBase

Fiecare lot este procurat de la un producător certificat WHO-GMP. Comenzile sunt expediate în ambalaje simple, fără marcă, de la partenerii noștri de onorare și acoperite de Politica noastră de Reexpediere Garantată: dacă un colet nu ajunge în 20 de zile lucrătoare, trimitem gratuit o nouă comandă, fără întrebări.

What is Oxyspas?

Oxyspas is a brand of oxybutynin chloride immediate-release tablets, available in 2.5 mg and 5 mg strengths. Internationally branded as Ditropan (US, UK, EU, AU), Cystrin (UK), Lyrinel XL (extended-release), Oxytrol (transdermal patch), Gelnique (gel). Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets per strength.

How oxybutynin works

Oxybutynin is a competitive antagonist at M1, M2 and M3 muscarinic acetylcholine receptors. The clinically relevant action is blockade of M3 receptors on the bladder detrusor smooth muscle — this reduces parasympathetic-driven detrusor contractions during the filling phase, decreasing urgency and incontinence episodes and increasing functional bladder capacity.

The dry-mouth, constipation, blurred-vision, and CNS side effects are the consequences of the SAME mechanism acting at non-bladder muscarinic receptors throughout the body — salivary glands (M3), gut (M2/M3), ciliary muscle of the eye (M3), and the central nervous system (M1/M2). Newer “uroselective” antimuscarinics (solifenacin, darifenacin) have somewhat better selectivity for bladder M3, but the difference is modest. Mirabegron, a β3 agonist with a completely different mechanism, avoids these side effects altogether.

When oxybutynin is used

  • Overactive bladder syndrome (OAB) with urgency, frequency, urge incontinence — the licensed indication
  • Neurogenic detrusor overactivity (multiple sclerosis, spinal cord injury, spina bifida)
  • Nocturnal enuresis (bedwetting) in children >5 years — sometimes used as second-line after desmopressin
  • Off-label: hyperhidrosis — occasionally used for excessive sweating because the same anticholinergic mechanism reduces sweat production. Side effects often outweigh benefit unless localised topical formulations are used.

Dozaj și mod de administrare

Adults:

  • Standard starting dose: 5 mg twice daily; increase to 5 mg three times daily if needed (maximum 20 mg/day in younger patients)
  • Sensitive or elderly: start at 2.5 mg twice daily and increase only if tolerated
  • Take with or without food. Drink plenty of water.
  • Effect on urgency develops within 1-2 weeks; full effect in 4-8 weeks

Children >5 years for nocturnal enuresis: 2.5-5 mg at bedtime, paediatric supervision essential.

Renal/hepatic impairment: reduce starting dose; titrate cautiously. Severe hepatic impairment is a relative contraindication.

Efecte secundare și siguranță

  • Foarte frecvente (mai mult de 1 din 10): dry mouth (the leading reason for discontinuation), constipation, dizziness
  • Frecvente: blurred vision (cyclopentolate-like effect), drowsiness, headache, nausea, urinary retention or hesitancy, palpitations, hot flushes, dry skin
  • Mai puțin frecvente: impaired heat tolerance (reduced sweating — risk in hot weather, exercise), confusion, hallucinations (especially in older adults), tachycardia
  • Rare dar grave: acute angle-closure glaucoma (in predisposed individuals), severe constipation / paralytic ileus, urinary retention, allergic angioedema, QT prolongation
  • In elderly: increased falls risk, cognitive slowing, delirium, possibly increased long-term dementia risk — see geriatric section below

Anticholinergic burden & the elderly

⚠️ Anticholinergic burden in the elderly. Anticholinergic medications increase the risk of falls, cognitive decline, delirium, and dementia in older adults — particularly when stacked with other anticholinergics (diphenhydramine, hydroxyzine, amitriptyline, hyoscyamine, scopolamine, oxybutynin, tolterodine). For patients aged 65+, mirabegron (a β3-agonist) is the preferred first-line OAB drug. The 2023 American Geriatrics Society Beers Criteria classifies all anticholinergic OAB drugs as “potentially inappropriate” in older adults.

Oxybutynin is the most strongly anticholinergic of the OAB drugs and crosses the blood-brain barrier readily. In adults aged 65+, the cumulative anticholinergic burden from oxybutynin (often combined with other anticholinergics in the medication list) is associated with measurable cognitive decline, increased fall risk, and emerging evidence of long-term dementia risk in observational studies.

Practical implications:

  • If you are 65+ and starting OAB therapy, ask your doctor about mirabegron first — it has equivalent efficacy without the anticholinergic burden
  • If oxybutynin is essential, use the lowest effective dose and consider transdermal or topical formulations (lower CNS exposure)
  • Audit your full medication list for other anticholinergics (diphenhydramine, hydroxyzine, amitriptyline, quetiapine, tolterodine, hyoscyamine) — deprescribe where possible
  • Review at 6-12 months: is the benefit worth the side-effect cost?

Contraindicații și avertizări

Do not take oxybutynin if you have:

  • Untreated narrow-angle glaucoma
  • Urinary retention or significant bladder outlet obstruction
  • Severe gastrointestinal motility disorders (paralytic ileus, severe ulcerative colitis, toxic megacolon)
  • Myasthenia gravis
  • Hypersensitivity to oxybutynin

Folosiți cu precauție dacă aveți: elderly age (see above), benign prostatic hyperplasia (urinary retention risk), reflux oesophagitis, autonomic neuropathy, hyperthyroidism, coronary artery disease, hypertension, arrhythmia, dementia or cognitive impairment.

Sarcină și alăptare: use only if benefit outweighs risk.

Interacțiuni medicamentoase

  • Other anticholinergics — additive effects; minimise stacking. Common offenders: diphenhydramine, hydroxyzine, amitriptyline, nortriptyline, paroxetine, quetiapine, hyoscyamine, scopolamine, tolterodine, atropine
  • CNS depressants (alcohol, benzodiazepines, opioids) — additive sedation
  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine for dementia) — OPPOSING mechanisms; co-prescribing both is irrational and the combination is associated with worse outcomes than either alone
  • Inhibitori puternici ai CYP3A4 (ketoconazole, itraconazole, ritonavir) — increase oxybutynin levels
  • Drugs delayed by reduced GI motility — absorption may be altered (sustained-release formulations, levodopa)

How oxybutynin compares

MedicamentClasăTrăsătură notabilă
OxybutyninAnticholinergic (M1-M3)Cheapest, most prescribed; highest dry mouth + cognitive risk
Tolterodine / Terol LAAnticholinergicBetter-tolerated than oxybutynin; LA form once daily
Solifenacin / darifenacinSelective M3 anticholinergicSlightly less dry mouth than oxybutynin
Mirabegron (Mirago)β3 agonistPreferred first-line in 65+; no anticholinergic burden
Flavoxate (Urispas)AntispasmodicMild; useful for urinary spasm post-procedure

Depozitare și termen de valabilitate

Store Oxyspas tablets below 25°C in the original blister pack. Protect from moisture and light. Keep out of reach of children. Do not use after the expiry date.

Întrebări frecvente

Why does oxybutynin cause such bad dry mouth?

Oxybutynin blocks the M3 muscarinic receptors that drive saliva production in the salivary glands — the same receptor it blocks in the bladder. The dry mouth is a direct extension of the wanted bladder effect to an unwanted side. Sugar-free chewing gum, frequent sips of water, and a saliva substitute (Biotene, Glandosane) help. If dry mouth is intolerable, switching to mirabegron (no antimuscarinic effect) is usually the right move.

Should I take oxybutynin if I am over 65?

The 2023 American Geriatrics Society Beers Criteria classifies oxybutynin as “potentially inappropriate” in older adults — cumulative anticholinergic burden is associated with falls, cognitive slowing, delirium, and possibly long-term dementia risk. Discuss mirabegron first with your doctor; it has equivalent efficacy for OAB with none of these side effects. If oxybutynin is essential, use the lowest effective dose and review the rest of your medications for other anticholinergics that could be deprescribed.

How quickly does oxybutynin work?

Initial reduction in urgency and frequency is typically noticeable within the first week, with the full effect over 4-8 weeks. If there is no benefit by 8 weeks at maximum tolerated dose, switching to a different OAB drug (mirabegron, solifenacin, tolterodine LA) is reasonable.

Can I drink alcohol with oxybutynin?

Alcohol amplifies the drowsiness and dizziness side effects. Moderate occasional alcohol is generally fine but heavy or regular use is best avoided.

Will oxybutynin affect my driving?

Drowsiness and blurred vision can affect driving, especially in the first few weeks. Avoid driving until you know how oxybutynin affects you.

Why am I overheating in summer?

Oxybutynin reduces sweating (anticholinergic effect on sweat glands), so you can become unable to thermoregulate properly in hot weather or with exercise. Stay well-hydrated, avoid extreme heat, and consider switching to mirabegron if you live in a hot climate or do strenuous outdoor activity.

Can I take oxybutynin with my dementia drugs (donepezil, rivastigmine)?

This is a common but problematic combination — oxybutynin (anticholinergic) directly opposes the mechanism of donepezil/rivastigmine/galantamine (cholinesterase inhibitors that increase acetylcholine). Studies show worse cognitive outcomes when both are co-prescribed than with either alone. If both seem necessary, discuss with your doctor whether to switch the OAB drug to mirabegron.

Is the 2.5 mg or 5 mg strength right for me?

Most adults start at 5 mg twice daily. Older patients, those who weigh under 50 kg, those with renal/hepatic impairment, and anyone susceptible to anticholinergic side effects start at 2.5 mg twice daily and increase only if tolerated. The 2.5 mg strength of Oxyspas allows this gentler titration without splitting tablets.

Where can I order Oxyspas online?

You can order Oxyspas 2.5 mg or 5 mg tablets from MedsBase in pack sizes of 30, 60, 90 or 180 tablets. Orders ship worldwide with discreet packaging. Oxybutynin is specialist-supervised worldwide.

⚕ Dezaprobare medicală. Această pagină are scop informativ și nu înlocuiește sfatul medical al unui profesionist calificat în domeniul sănătății. Consultați întotdeauna medicul sau farmacistul înainte de a începe, modifica sau întrerupe orice tratament pentru simptome urinare sau de prostată — acestea pot fi semnele timpurii ale unor afecțiuni (infecție urinară, cancer de prostată, pietre vezicale) care necesită diagnostic și tratament țintit, nu doar ameliorare simptomatică. MedsBase nu oferă diagnostic, prescripție sau recomandări clinice.

Alternative conexe

Alte produse din Sănătate generală pe care clienții le vizualizează de asemenea:

Mai multe opțiuni în vezică și prostată

Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.

Concentrație

2,5 mg, 5 mg

Cantitate

30 Comprimat/e, 60 Comprimat/e, 90 Comprimat/e, 180 Comprimat/e

Recenzii

Nu există recenzii încă

Adăugați o recenzie
Oxyspas Oxyspas
Evaluare*
0/5
* Evaluarea este obligatorie
* Răspunsul este obligatoriu
Recenzia dvs.
* Recenzia este obligatorie
Nume
* Numele este obligatoriu
Adăugați fotografii sau videoclip la recenzia dvs.

Întrebări și răspunsuri

Pune o întrebare
Oxyspas Oxyspas
Întrebarea ta
* Întrebarea este obligatorie
Nume
* Numele este obligatoriu
Nu există întrebări încă